Hikma Pharmaceuticals plc

Company characteristics

Assessed report publication year
Financial year end 31/12/23
Sector Health Care
Head office United Kingdom
Primary listing London Stock Exchange
GBP market cap 3,955,145,727
Net profit margin 6.68%
CEO tenure 0.3 years
Employee count 8,967
FRF draft assessment response No

Reward scrutiny

Living wage accredited No Living wage (calculation for operating regions) Yes
Living hours accredited No Tax reporting (GRI 207) No

Remuneration policies

Remuneration committee 100% independent Yes Remuneration committee discretion applied Yes
Remuneration committee discretion (direction) Up
Director from workforce No Trade union relations (disclosure) No
Worker consultation on top pay (disclosure) No 80%+ shareholder support on pay Yes

Reward outcomes

CEO total pay (GBP) 1,217,908 CEO total pay change -73.62%
CEO pay ratio (to median employee) Percentage point increase in maximum variable remuneration
Pension award parity between CEO and wider workforce Yes Pay of the next highest exec compared to CEO 182.91%
Gender pay gap (mean data) N/A Gender pay (women % in top quartile)
Ethnicity pay gap (disclosure) No Total dividend (USD) 159,178,587